Matt Dun: The First Therapeutic Step Forward for H3K27-Altered Diffuse Midline Glioma
Matt Dun, Professor of Paediatric Haematology/Oncology Research at School of Biomedical Science and Pharmacy, shared a post on LinkedIn by Jazz Pharmaceuticals, adding:
“The first therapeutic step forward for H3K27-altered diffuse midline glioma (DMG) when everything else fails.
In 2018, we began investigating the utility of ONC201 (now known as dordaviprone, commercialised as Modeyso), and helped unravel the biological mechanisms that underpin its clinical activity in patients with DMG.
Since then, our team has contributed to, led, and supported a growing body of research establishing dordaviprone as an option for patients with relapsed DMG:
Key publications:
1. – Neuro-Oncology Advances
2. – Neuro-Oncology
3. – The Lancet Oncology
4. – Cancer Research
5. – Neuro-Oncology
6. – Cancer Discovery
7. – Neuro-Oncology
8. – Neuro-Oncology
Supporting studies testing clinical benefit in relapsed DMG – Journal of Clinical Oncology.
This is not cure, and more evidence is needed in the upfront setting, but it represents an option at advanced disease. Innovative clinical trials, grounded in robust data, remain urgently needed particularly for DIPG patients.
Dun Lab is focused on building safe, rational combination strategies: for patients at all disease stages.
Our support and progress of this has been made possible through a continuing extraordinary international collaboration:
– University of Newcastle, Hunter Medical Research Institute (HMRI),
– University of Michigan,
– University of California, San Francisco,
– Children’s National Hospital,
– University of Zurich,
– University of Navarra,
– EPFL
– Prinses Máxima Centrum voor kinderoncologie,
– Hudson Institute of Medical Research,
– Murdoch Children’s Research Institute (MCRI) Children’s Cancer Institute
– and many more.”
Quoting Jazz Pharmaceuticals’ post below:
“We are pleased to share that a new treatment for recurrent H3 K27M-mutant diffuse midline glioma received FDA accelerated approval today. This milestone is a meaningful advancement in the treatment of this ultra-rare and aggressive brain tumor, which primarily affects children and young adults.
We congratulate our combined Chimerix and Jazz team, and the community who worked together tirelessly to bring this treatment forward. We would like to extend our thanks to the patients, advocates, clinicians, principal investigators, scientists, regulators and partner institutions who made this possible.
More posts featuring Jazz Pharmaceuticals on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023